Shikonin and its analogs inhibit cancer cell glycolysis by targeting tumor pyruvate kinase-M2

Oncogene

Volumn 30, Issue 42, 2011, Pages 4297-4306

  Chen, J ^a,b,c   Xie, J ^a,b,c   Jiang, Z ^d   Wang, B ^a,b,c   Wang, Y ^d   Hu, X ^a,b,c  

^a Cancer Institute (A Key Laboratory for Cancer Prevention and Intervention   (China)

^b A Key Laboratory of Molecular Biology in Medical Sciences   (China)

^c ZHEJIANG UNIVERSITY SCHOOL OF MEDICINE   (China)

^d ZHEJIANG UNIVERSITY   (China)

Author keywords

alkannin; glycolysis; inhibitor; pyruvate kinase M2; shikonin

Indexed keywords

ALKANNIN; LACTIC ACID; PYRUVATE KINASE; PYRUVATE KINASE ISOENZYME L; PYRUVATE KINASE M1; PYRUVATE KINASE M2; SHIKONIN; UNCLASSIFIED DRUG;

ARTICLE; CANCER CELL; CANCER INHIBITION; CELL DEATH; CELL PROLIFERATION; CELL SURVIVAL; DRUG POTENCY; DRUG TARGETING; ENANTIOMER; ENZYME ACTIVITY; GLUCOSE INTAKE; GLYCOLYSIS; PRIORITY JOURNAL;

ANTINEOPLASTIC AGENTS; CELL LINE, TUMOR; ENZYME INHIBITORS; GLUCOSE; GLYCOLYSIS; HUMANS; LACTIC ACID; NAPHTHOQUINONES; NEOPLASMS; PYRUVATE KINASE;

EID: 80054883247     PISSN: 09509232     EISSN: 14765594     Source Type: Journal    
DOI: 10.1038/onc.2011.137     Document Type: Article

References (43)

1. Ahn BZ, Baik KU, Kweon GR, Lim K, Hwang BD. (1995). Acylshikonin analogues: synthesis and inhibition of DNA topo-isomerase-I. J Med Chem 38: 1044-1047.
2. Altenberg B, Greulich KO. (2004). Genes of glycolysis are ubiquitously overexpressed in 24 cancer classes. Genomics 84: 1014-1020. (Pubitemid 39469126)
3. Anderson SR, Florini JR, Vestling CS. (1964). Rat liver lactate dehydrogenase. 3. Kinetics and specificity. J Biol Chem 239: 2991-2997.
4. Bailly C. (2000). Topoisomerase I poisons and suppressors as anticancer drugs. Curr Med Chem 7: 20.
5. Christofk HR, Vander Heiden MG, Harris MH, Ramanathan A, Gerszten RE, Wei R et al. (2008). The M2 splice isoform of pyruvate kinase is important for cancer metabolism and tumour growth. Nature 452: 230-233. (Pubitemid 351380249)
6. DeBerardinis RJ, Lum JJ, Hatzivassiliou G, Thompson CB. (2008). The biology of cancer: metabolic reprogramming fuels cell growth and proliferation. Cell Metab 7: 11-20.
7. Degterev A, Huang Z, Boyce M, Li Y, Jagtap P, Mizushima N et al. (2005). Chemical inhibitor of nonapoptotic cell death with therapeutic potential for ischemic brain injury. Nat Chem Biol 1: 112-119.
8. Degterev A, Hitomi J, Germscheid M, Ch'en IL, Korkina O, Teng X et al. (2008). Identification of RIP1 kinase as a specific cellular target of necrostatins. Nat Chem Biol 4: 313-321. (Pubitemid 351550892)
9. Dombrauckas JD, Santarsiero BD, Mesecar AD. (2005). Structural basis for tumor pyruvate kinase M2 allosteric regulation and catalysis. Biochemistry 44: 9417-9429. (Pubitemid 40962040)
10. Gatenby RA, Gillies RJ. (2004). Why do cancers have high aerobic glycolysis? Nat Rev Cancer 4: 891-899. (Pubitemid 39472955)
11. Guo XP, Zhang XY, Zhang SD. (1991). [Clinical trial on the effects of shikonin mixture on later stage lung cancer]. Zhong Xi Yi Jie He Za Zhi 11: 598-599, 580.
12. Han W, Li L, Qiu S, Lu Q, Pan Q, Gu Y et al. (2007). Shikonin circumvents cancer drug resistance by induction of a necroptotic death. Mol Cancer Ther 6: 1641-1649. (Pubitemid 46954031)
13. Han W, Xie J, Li L, Liu Z, Hu X. (2009). Necrostatin-1 reverts shikonin-induced necroptosis to apoptosis. Apoptosis 14: 674-686.
14. Hirayama A, Kami K, Sugimoto M, Sugawara M, Toki N, Onozuka H et al. (2009). Quantitative metabolome profiling of colon and stomach cancer microenvironment by capillary electrophoresis time-of-flight mass spectrometry. Cancer Res 69: 4918-4925.
15. Hitomi J, Christofferson DE, Ng A, Yao J, Degterev A, Xavier RJ et al. (2008). Identification of a molecular signaling network that regulates a cellular necrotic cell death pathway. Cell 135: 1311-1323.
16. Hsu PP, Sabatini DM. (2008). Cancer cell metabolism: Warburg and beyond. Cell 134: 703-707.
17. Hu X, Xuan Y. (2008). Bypassing cancer drug resistance by activating multiple death pathways-a proposal from the study of circumventing cancer drug resistance by induction of necroptosis. Cancer Lett 259: 127-137. (Pubitemid 50015326)
18. Ibsen KH. (1977). Interrelationships and functions of the pyruvate kinase isozymes and their variant forms: a review. Cancer Res 37: 341-353. (Pubitemid 8030371)
19. Ikeda Y, Noguchi T. (1998). Allosteric regulation of pyruvate kinase M2 isozyme involves a cysteine residue in the intersubunit contact. J Biol Chem 273: 12227-12233. (Pubitemid 28240587)
20. Imamura K, Tanaka T, Nishina T, Nakashima K, Miwa S. (1973). Studies on pyruvate kinase (PK) deficiency. II. Electrophoretic, kinetic and immunological studies on pyruvate kinase of erythro-cytes and other tissues. J Biochem 74: 1165-1175.
21. Jurica MS, Mesecar A, Heath PJ, Shi W, Nowak T, Stoddard BL. (1998). The allosteric regulation of pyruvate kinase by fructose-1, 6-bisphosphate. Structure 6: 195-210. (Pubitemid 28153883)
22. Kim SH, Kang IC, Yoon TJ, Park YM, Kang KS, Song GY et al. (2001). Antitumor activities of a newly synthesized shikonin derivative, 2-hyim-DMNQ-S-33. Cancer Lett 172: 171-175. (Pubitemid 32889713)
23. Li L, Han W, Gu Y, Qiu S, Lu Q, Jin J et al. (2007). Honokiol induces a necrotic cell death through the mitochondrial permeability transition pore. Cancer Res 67: 4894-4903. (Pubitemid 46910198)
24. Liu K, Lu H, Hou L, Qi Z, Teixeira C, Barbault F et al. (2008). Design, synthesis, and biological evaluation of N-carboxyphenyl-pyrrole derivatives as potent HIV fusion inhibitors targeting gp41. J Med Chem 51: 7843-7854.
25. Masuda Y, Nishida A, Hori K, Hirabayashi T, Kajimoto S, Nakajo S et al. (2003). Beta-hydroxyisovalerylshikonin induces apoptosis in human leukemia cells by inhibiting the activity of a polo-like kinase 1 (PLK1). Oncogene 22: 1012-1023. (Pubitemid 36313145)
26. Masuda Y, Shima G, Aiuchi T, Horie M, Hori K, Nakajo S et al. (2004). Involvement of tumor necrosis factor receptor-associated protein 1 (TRAP1) in apoptosis induced by beta-hydroxyisovaler-ylshikonin. J Biol Chem 279: 42503-42515. (Pubitemid 39372134)
27. Mazurek S. (2007). Pyruvate kinase type M2: a key regulator within the tumour metabolome and a tool for metabolic profiling of tumours. Ernst Schering Found Symp Proc 4: 99-124.
28. Mazurek S, Boschek CB, Hugo F, Eigenbrodt E. (2005). Pyruvate kinase type M2 and its role in tumor growth and spreading. Semin Cancer Biol 15: 300-308. (Pubitemid 41058775)
29. Mazurek S, Eigenbrodt E. (2003). The tumor metabolome. Anticancer Res 23: 1149-1154. (Pubitemid 36750932)
30. Mazurek S, Grimm H, Boschek CB, Vaupel P, Eigenbrodt E. (2002). Pyruvate kinase type M2: a crossroad in the tumor metabolome. Br J Nutr 87(Suppl 1): S23-S29. (Pubitemid 34134101)
31. Nakaya K, Miyasaka T. (2003). A shikonin derivative, beta-hydro- xyisovalerylshikonin, is an ATP-non-competitive inhibitor of protein tyrosine kinases. Anticancer Drugs 14: 683-693. (Pubitemid 37357692)
32. Noguchi T, Inoue H, Tanaka T. (1986). The M1-and M2-type isozymes of rat pyruvate kinase are produced from the same gene by alternative RNA splicing. J Biol Chem 261: 13807-13812. (Pubitemid 17196407)
33. Noguchi T, Yamada K, Inoue H, Matsuda T, Tanaka T. (1987). The L-and R-type isozymes of rat pyruvate kinase are produced from a single gene by use of different promoters. J Biol Chem 262: 14366-14371.
34. Papageorgiou VP AA, Couladouros EA, Hepworth D, Nicolaou KC. (1999). The chemistry and biology of alkannin, shikonin, and related naphthazarin natural products. Angewandte Chemie International Edition 38: 32.
35. Parkison C, Ashizawa K, McPhie P, Lin K, Cheng S. (1991). The monomer of pyruvate kinase, subtype M1, is both a kinase and a cytosolic thyroid hormone binding protein. Biochem Biophys Res Commun 179: 668-674.
36. Shimada N, Shinagawa T, Ishii S. (2008). Modulation of M2-type pyruvate kinase activity by the cytoplasmic PML tumor suppressor protein. Genes Cells 13: 245-254. (Pubitemid 351292280)
37. Spoden GA, Mazurek S, Morandell D, Bacher N, Ausserlechner MJ, Jansen-Durr P et al. (2008). Isotype-specific inhibitors of the glycolytic key regulator pyruvate kinase subtype M2 moderately decelerate tumor cell proliferation. Int J Cancer 123: 312-321. (Pubitemid 351842015)
38. Spoden GA, Rostek U, Lechner S, Mitterberger M, Mazurek S, Zwerschke W. (2009). Pyruvate kinase isoenzyme M2 is a glycolytic sensor differentially regulating cell proliferation, cell size and apoptotic cell death dependent on glucose supply. Exp Cell Res 315: 2765-2774.
39. Vander Heiden MG, Cantley LC, Thompson CB. (2009). Understanding the Warburg effect: the metabolic requirements of cell proliferation. Science 324: 1029-1033.
40. Vander Heiden MG, Christofk HR, Schuman E, Subtelny AO, Sharfi H, Harlow EE et al. (2010). Identification of small molecule inhibitors of pyruvate kinase M2. Biochem Pharmacol 79: 1118-1124.
41. Warburg O. (1956). On the origin of cancer cells. Science 123: 309-314.
42. Xuan Y, Hu X. (2009). Naturally-occurring shikonin analogues-a class of necroptotic inducers that circumvent cancer drug resistance. Cancer Lett 274: 233-242.
43. Yang H, Zhou P, Huang H, Chen D, Ma N, Cui QC et al. (2009). Shikonin exerts antitumor activity via proteasome inhibition and cell death induction in vitro and in vivo. Int J Cancer 124: 2450-2459.